# US 2026/0076954 A1 · Compositions and methods for reducing cancer stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076954 A1
- Document ID: US20260076954A1
- Status: Published application
- Kind: A1
- Application number: 19/328,983
- Filed: 2025-09-15
- Published: 2026-03-19
- Earliest claimed: 2018-10-12
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, A Body Corporate
- Inventors: Craig Jordan; Clayton Smith; Courtney L. Jones; Brett Stevens
- Web page: https://patentgrep.com/patent/US20260076954A1

## CPC

- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/336: having three-membered rings, e.g. oxirane, fumagillin
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/635: having a heterocyclic ring, e.g. sulfadiazine
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compositions and methods for reducing cancer stem cells. In some aspects, the compositions and methods can comprise at least one metabolism modulating agent. In other aspects, the compositions and methods can comprise at least two metabolism modulating agents.

## Claims

### Claim 1

A combination for treating acute myeloid leukemia (AML) in a patient in need thereof, the combination comprising venetoclax and etomoxir.

### Claim 2 (depends on 1)

The combination of claim 1, wherein the combination further comprises azacitidine.

### Claim 3 (depends on 2)

The combination of claim 2, wherein the venetoclax, azacitidine, and etomoxir are formulated for administration to the patient concomitantly.

### Claim 4 (depends on 2)

The combination of claim 2, wherein the venetoclax, azacitidine, and etomoxir are formulated for administration to the patient sequentially.

### Claim 5 (depends on 2)

The combination of claim 2, wherein the venetoclax, azacitidine, and etomoxir are formulated for administration orally, intravenously, subcutaneously, or any combination thereof.

### Claim 6 (depends on 1)

The combination of claim 1, wherein the venetoclax is formulated for administration in a ramp-up schedule over the course of 5 weeks.

### Claim 7 (depends on 1)

The combination of claim 1, wherein the combination is administered to the patient in an amount sufficient to induce cell death in leukemia stem cells in the patient.

### Claim 8

A combination for treating myelodysplastic syndrome (MDS) in a patient in need thereof, the combination comprising venetoclax and omacetaxine mepesuccinate.

### Claim 9 (depends on 8)

The combination of claim 8, wherein the venetoclax and omacetaxine mepesuccinate are formulated for administration to the patient concomitantly.

### Claim 10 (depends on 8)

The combination of claim 8, wherein the venetoclax and omacetaxine mepesuccinate are formulated for administration to the patient sequentially.

### Claim 11 (depends on 8)

The combination of claim 8, wherein the venetoclax and omacetaxine mepesuccinate are formulated for administration orally, intravenously, subcutaneously, or any combination thereof.

### Claim 12 (depends on 8)

The combination of claim 8, wherein the venetoclax is formulated for administration in a ramp-up schedule over the course of 5 weeks.

### Claim 13

The combination of 8, wherein the combination is administered to the patient in an amount sufficient to induce cell death in MDS stem cells in the patient.

### Claim 14

A method for treating MDS in a patient in need thereof comprising administering to the patient a combination of venetoclax, azacitidine, and omacetaxine mepesuccinate.

### Claim 15

A method for treating AML in a patient with relapsed AML in need thereof comprising administering to the patient a combination of veneticlax and azacitidine.

### Claim 16 (depends on 15)

The method of claim 15, further comprising administering to the patient in need thereof one or more additional therapeutic agents selected from a CD36 inhibitor and a CPT1 inhibitor.

### Claim 17 (depends on 1)

The method of claim 1, wherein the CD36 inhibitor comprises sorbitan sesquioleate.

### Claim 18 (depends on 16)

The method of claim 16, wherein the CPT1 inhibitor comprises etomoxir.

### Claim 19

A method for treating AML in a patient in need thereof comprising administering a combination of venetoclax and azacitidine to the patient in need thereof, wherein a sample from the patient was genotyped and identified as having a mutation in isocitrate dehydrogenase (IDH) isoform 1 or 2.

### Claim 20 (depends on 19)

The method of claim 19, wherein the sample is further genotyped for mutations in PTPN11 or other RAS pathway genes.
